|
|
Article: BAXTER, RHONE-POULENC RORER RESOLVE ALL DISPUTES INVOLVING FACTOR VIII:C PATENTS; SIGN PURCHASING AGREEMENT FOR BAXTER PRODUCTS
- Article from:
- PR Newswire
- Article date:
- May 12, 1993
CopyrightCOPYRIGHT 1993 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DEERFIELD, Ill., May 12 /PRNewswire/ -- Baxter International (NYSE: BAX) announced today that it has reached a worldwide settlement with Rhone-Poulenc Rorer (NYSE: RPR) of Collegeville, Pa., involving a longstanding patent lawsuit concerning ultra-pure Factor VIII:C concentrates for the treatment of hemophilia. Baxter and Rhone-Poulenc Rorer also agreed to a long-term agreement for Rhone-Poulenc Rorer to purchase products from Baxter, and an agreement for Baxter to supply recombinant Factor VIII:C to Rhone-Poulenc Rorer. The settlement will be filed in the U.S. District Court in Delaware.
Factor VIII:C is the clotting protein missing from the blood of people with ...